董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul B. Bolno | 男 | President,Chief Executive Officer and Director | 49 | 266.80万美元 | 未持股 | 2023-06-12 |
| Ken Takanashi | 男 | Director | 59 | 9.27万美元 | 未持股 | 2023-06-12 |
| Heidi L. Wagner | 女 | Director | 58 | 10.77万美元 | 未持股 | 2023-06-12 |
| Christian Henry | 男 | Chairman of the Board | 55 | 14.42万美元 | 未持股 | 2023-06-12 |
| Adrian Rawcliffe | 男 | Director | 51 | 11.07万美元 | 未持股 | 2023-06-12 |
| Aik Na Tan | 女 | Director | 52 | 9.42万美元 | 未持股 | 2023-06-12 |
| Mark H. N. Corrigan | 男 | Director | 65 | 11.67万美元 | 未持股 | 2023-06-12 |
| Gregory L. Verdine | 男 | Director | 64 | 62.81万美元 | 未持股 | 2023-06-12 |
| Peter Kolchinsky | 男 | Director | 46 | 9.27万美元 | 未持股 | 2023-06-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul B. Bolno | 男 | President,Chief Executive Officer and Director | 49 | 266.80万美元 | 未持股 | 2023-06-12 |
| Christopher Francis | 男 | Senior Vice President, Corporate Development, Head of Emerging Areas | 45 | 168.23万美元 | 未持股 | 2023-06-12 |
| Kyle Moran | 男 | Chief Financial Officer | 53 | 114.88万美元 | 未持股 | 2023-06-12 |
| Chandra Vargeese | 女 | Chief Technology Officer, Head of Platform Discovery Sciences | 62 | 123.18万美元 | 未持股 | 2023-06-12 |
董事简历
中英对照 | 中文 | 英文- Paul B. Bolno
-
Paul B. Bolno，自2013年12月起担任公司的总裁和首席执行官，也是董事。在加入公司之前，他在GlaxoSmithKline担任不同的职位（2009-2013年），包括全球业务拓展副总裁，亚洲（Asia）业务拓展和投资负责人；全球神经科学业务拓展负责人；新加坡（Singapore）Glaxo Welcome Manufacturing, Pte. Ltd.的董事；肿瘤科业务拓展副总裁，他建立了GlaxoSmithKline的全球肿瘤业务并担任肿瘤执行团队、肿瘤商业董事会和癌症研究执行团队的成员。在GlaxoSmithKline之前，他担任Two River 有限责任公司（Two River LLC，一家健康保健私人股权公司）的研究董事（2004-2009年）。他拥有MCP哈内曼医学院（MCP-Hahnemann School of Medicine）医学学位和德雷克塞尔大学（Drexel University）工商管理硕士学位。他是德雷克塞尔大学医学院（Drexel University College of Medicine）的普通外科住院医师和心胸外科博士后研究师。
Paul B. Bolno,has served as Wave Life Sciences Ltd. President and Chief Executive Officer since December 2013 and as a director since April 2014. Since June 2020, Dr. Bolno has also served on the board of directors of SQZ Biotechnologies, a publicly-traded life sciences company, and since May 2020, he has served as Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator (NATA) in the United Kingdom. Prior to joining Wave Life Sciences Ltd. , he served at GlaxoSmithKline from 2009 to 2013 in various roles, including Vice President, Worldwide Business Development—Head of Asia BD and Investments, Head of Global Neuroscience BD, a director of Glaxo Welcome Manufacturing, Pte. Ltd. in Singapore and Vice President, Business Development for the Oncology Business Unit, where he helped establish GlaxoSmithKline's global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GlaxoSmithKline, he served as director of Research at Two River LLC, a health care private equity firm from 2004 to 2009. Dr. Bolno earned a medical degree from MCP-Hahnemann School of Medicine and an M.B.A. from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine. - Paul B. Bolno，自2013年12月起担任公司的总裁和首席执行官，也是董事。在加入公司之前，他在GlaxoSmithKline担任不同的职位（2009-2013年），包括全球业务拓展副总裁，亚洲（Asia）业务拓展和投资负责人；全球神经科学业务拓展负责人；新加坡（Singapore）Glaxo Welcome Manufacturing, Pte. Ltd.的董事；肿瘤科业务拓展副总裁，他建立了GlaxoSmithKline的全球肿瘤业务并担任肿瘤执行团队、肿瘤商业董事会和癌症研究执行团队的成员。在GlaxoSmithKline之前，他担任Two River 有限责任公司（Two River LLC，一家健康保健私人股权公司）的研究董事（2004-2009年）。他拥有MCP哈内曼医学院（MCP-Hahnemann School of Medicine）医学学位和德雷克塞尔大学（Drexel University）工商管理硕士学位。他是德雷克塞尔大学医学院（Drexel University College of Medicine）的普通外科住院医师和心胸外科博士后研究师。
- Paul B. Bolno,has served as Wave Life Sciences Ltd. President and Chief Executive Officer since December 2013 and as a director since April 2014. Since June 2020, Dr. Bolno has also served on the board of directors of SQZ Biotechnologies, a publicly-traded life sciences company, and since May 2020, he has served as Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator (NATA) in the United Kingdom. Prior to joining Wave Life Sciences Ltd. , he served at GlaxoSmithKline from 2009 to 2013 in various roles, including Vice President, Worldwide Business Development—Head of Asia BD and Investments, Head of Global Neuroscience BD, a director of Glaxo Welcome Manufacturing, Pte. Ltd. in Singapore and Vice President, Business Development for the Oncology Business Unit, where he helped establish GlaxoSmithKline's global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GlaxoSmithKline, he served as director of Research at Two River LLC, a health care private equity firm from 2004 to 2009. Dr. Bolno earned a medical degree from MCP-Hahnemann School of Medicine and an M.B.A. from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine.
- Ken Takanashi
-
Ken Takanashi，自2012年7月在公司董事会工作。2002年Takanashi先生担任Shin Nippon Biomedical Laboratories Ltd.（SNBL）和子公司的不同的执行管理和董事职位，目前担任监督业务部门高级管理董事。Takanashi先生担任SNBL USA, Ltd.（Shin Nippon Biomedical Laboratories的子公司）的财务总监（2012-2014年）。他拥有华威大学（University of Warwick）工商管理硕士学位和东京大学（University of Tokyo）学士学位，他也是一名注册会计师。
Ken Takanashi,has served as a director since July 2012. Since 2002, Mr. Takanashi has served in various executive management and director roles at Shin Nippon Biomedical Laboratories Ltd. ("SNBL") and its affiliates and currently serves as its Executive Vice President, Representative Director. Mr. Takanashi was the Chief Financial Officer of SNBL USA, Ltd., a subsidiary of Shin Nippon Biomedical Laboratories, from 2012 to 2014. Since 2016, Mr. Takanashi has also served on the board of directors of Satsuma Pharmaceuticals, Inc., a biopharmaceutical company that was previously publicly-traded and became a privately-held company and wholly-owned subsidiary of SNBL on June 8, 2023. Mr. Takanashi also serves as a member of the board of directors of TMS Co., Ltd., a biopharmaceutical company listed on the Tokyo Stock Exchange, since March 2022. Mr. Takanashi earned an M.B.A. from the University of Warwick and received his bachelor's degree from the University of Tokyo and is a Chartered Public Accountant. - Ken Takanashi，自2012年7月在公司董事会工作。2002年Takanashi先生担任Shin Nippon Biomedical Laboratories Ltd.（SNBL）和子公司的不同的执行管理和董事职位，目前担任监督业务部门高级管理董事。Takanashi先生担任SNBL USA, Ltd.（Shin Nippon Biomedical Laboratories的子公司）的财务总监（2012-2014年）。他拥有华威大学（University of Warwick）工商管理硕士学位和东京大学（University of Tokyo）学士学位，他也是一名注册会计师。
- Ken Takanashi,has served as a director since July 2012. Since 2002, Mr. Takanashi has served in various executive management and director roles at Shin Nippon Biomedical Laboratories Ltd. ("SNBL") and its affiliates and currently serves as its Executive Vice President, Representative Director. Mr. Takanashi was the Chief Financial Officer of SNBL USA, Ltd., a subsidiary of Shin Nippon Biomedical Laboratories, from 2012 to 2014. Since 2016, Mr. Takanashi has also served on the board of directors of Satsuma Pharmaceuticals, Inc., a biopharmaceutical company that was previously publicly-traded and became a privately-held company and wholly-owned subsidiary of SNBL on June 8, 2023. Mr. Takanashi also serves as a member of the board of directors of TMS Co., Ltd., a biopharmaceutical company listed on the Tokyo Stock Exchange, since March 2022. Mr. Takanashi earned an M.B.A. from the University of Warwick and received his bachelor's degree from the University of Tokyo and is a Chartered Public Accountant.
- Heidi L. Wagner
-
Heidi L. Wagner，自2019年9月起担任董事。Wagner女士目前担任ElevateBio, LLC（一家私营生物制药公司）的全球政府事务主管（自2023年3月以来）。Wagner女士还担任the University of Colorado Foundation的董事会成员。Wagner女士从2018年到2021年1月担任Global Blood Therapeutics, Inc.的政府事务和政策高级副总裁。在加入Global Blood Therapeutics之前，Wagner女士曾担任Alexion Pharmaceuticals, Inc.的全球政府事务高级副总裁和执行委员会成员（2012年至2018年），以及全球政府事务副总裁（2009年至2012年）。Wagner女士从2000年到2009年担任Genentech, Inc.的政府事务高级总监，从1998年到1999年担任政府事务总监。在此之前，她曾担任医疗保健领导委员会的卫生政策主任和顾问，并在Epstein Becker & Green和Groom & Nordberg以及美国众议院担任各种职务。Wagner女士目前担任the American Kidney Fund的董事会成员、the University of Colorado Foundation的受托人、the University of Colorado, College of Media, Communication and Information的顾问委员会成员。从2015年到2018年，她还担任欧洲制药企业家联合会的董事会成员。Wagner女士在George Mason University法学院获得法学博士学位，并在University of Colorado获得新闻和大众传播理学学士学位。
Heidi L. Wagner,has served as a director since September 2019. Ms. Wagner currently serves as Global Head of Government Affairs at ElevateBio, LLC, a privately-held biopharmaceutical company, a position she has held since March 2023. Ms. Wagner also serves as a member of the Board of Directors for the University of Colorado Foundation. Ms. Wagner served as Senior Vice President, Government Affairs and Policy at Global Blood Therapeutics, Inc., from 2018 through January 2021. Prior to joining Global Blood Therapeutics, Ms. Wagner served as Senior Vice President, Global Governmental Affairs and a member of the Executive Committee at Alexion Pharmaceuticals, Inc. from 2012 to 2018, and as Vice President, Global Government Affairs from 2009 to 2012. Ms. Wagner held the role of Senior Director of Government Affairs at Genentech, Inc. from 2000 to 2009, and as Director, Government Affairs from 1998 to 1999. Prior to that time, she served as Health Policy Director and Consultant at Healthcare Leadership Council, and in various roles at Epstein Becker & Green and Groom & Nordberg, and the U.S. House of Representatives. Ms. Wagner currently serves as a member of the board of directors of the American Kidney Fund, as a Trustee of the University of Colorado Foundation, and as an advisory board member of the University of Colorado, College of Media, Communication and Information. From 2015 to 2018, she also served as a member of the board of directors of the European Confederation of Pharmaceutical Entrepreneurs. Ms. Wagner earned a J.D. from George Mason University School of Law and received a Bachelor of Science in Journalism and Mass Communication from the University of Colorado. - Heidi L. Wagner，自2019年9月起担任董事。Wagner女士目前担任ElevateBio, LLC（一家私营生物制药公司）的全球政府事务主管（自2023年3月以来）。Wagner女士还担任the University of Colorado Foundation的董事会成员。Wagner女士从2018年到2021年1月担任Global Blood Therapeutics, Inc.的政府事务和政策高级副总裁。在加入Global Blood Therapeutics之前，Wagner女士曾担任Alexion Pharmaceuticals, Inc.的全球政府事务高级副总裁和执行委员会成员（2012年至2018年），以及全球政府事务副总裁（2009年至2012年）。Wagner女士从2000年到2009年担任Genentech, Inc.的政府事务高级总监，从1998年到1999年担任政府事务总监。在此之前，她曾担任医疗保健领导委员会的卫生政策主任和顾问，并在Epstein Becker & Green和Groom & Nordberg以及美国众议院担任各种职务。Wagner女士目前担任the American Kidney Fund的董事会成员、the University of Colorado Foundation的受托人、the University of Colorado, College of Media, Communication and Information的顾问委员会成员。从2015年到2018年，她还担任欧洲制药企业家联合会的董事会成员。Wagner女士在George Mason University法学院获得法学博士学位，并在University of Colorado获得新闻和大众传播理学学士学位。
- Heidi L. Wagner,has served as a director since September 2019. Ms. Wagner currently serves as Global Head of Government Affairs at ElevateBio, LLC, a privately-held biopharmaceutical company, a position she has held since March 2023. Ms. Wagner also serves as a member of the Board of Directors for the University of Colorado Foundation. Ms. Wagner served as Senior Vice President, Government Affairs and Policy at Global Blood Therapeutics, Inc., from 2018 through January 2021. Prior to joining Global Blood Therapeutics, Ms. Wagner served as Senior Vice President, Global Governmental Affairs and a member of the Executive Committee at Alexion Pharmaceuticals, Inc. from 2012 to 2018, and as Vice President, Global Government Affairs from 2009 to 2012. Ms. Wagner held the role of Senior Director of Government Affairs at Genentech, Inc. from 2000 to 2009, and as Director, Government Affairs from 1998 to 1999. Prior to that time, she served as Health Policy Director and Consultant at Healthcare Leadership Council, and in various roles at Epstein Becker & Green and Groom & Nordberg, and the U.S. House of Representatives. Ms. Wagner currently serves as a member of the board of directors of the American Kidney Fund, as a Trustee of the University of Colorado Foundation, and as an advisory board member of the University of Colorado, College of Media, Communication and Information. From 2015 to 2018, she also served as a member of the board of directors of the European Confederation of Pharmaceutical Entrepreneurs. Ms. Wagner earned a J.D. from George Mason University School of Law and received a Bachelor of Science in Journalism and Mass Communication from the University of Colorado.
- Christian Henry
-
Christian Henry自2016年11月起担任董事，自2017年10月起担任董事会主席。Henry先生还担任Ginkgo Bioworks（一家私人合成生物学公司）和Pacific Biosciences（一家上市的生命科学公司）的董事会成员。Henry先生曾于2015年至2017年1月担任Illumina，Inc.执行Vice President兼首席商务官，此前曾于2014年至2015年担任高级副总裁兼首席商务官，2012年至2014年担任高级副总裁基因组解决方案总经理高级副总裁，2010年至2012年，担任生命科学首席财务官和总经理；2009年至2010年，担任企业发展和首席财务官高级副总裁，；2007年至2009年，担任高级副总裁和首席财务官；2005年至2006年，担任Vice President和首席财务官。在加入Illumina，Inc.之前，Henry先生从2003年到2005年担任Tickets.com，Inc.的首席财务官。从1999年到2003年，Henry先生担任赛默飞世尔科技（Thermo Fisher Scientific）于2016年收购的Affymetrix，Inc.的Vice President、财务与公司财务总监。1997年，Henry先生加入Nektar Therapeutics（前身为Inhale Therapeutic Systems，Inc.），担任公司财务总监，后来从1997年到1999年担任其首席会计官。Henry先生于1996年担任Sugen，Inc.的总会计经理。他的职业生涯始于1992年任职Ernst&Young LLP，在那里他曾担任高级会计师（直到1996年）。Henry先生在加州大学圣地亚哥分校（University of California，San Diego）获得生物化学和细胞生物学学士学位，并在加州大学欧文分校（University of California，Irvine）获得金融工商管理硕士学位。
Christian Henry,has served as a director since November 2016, and as Chairman of Wave Life Sciences Ltd. Board since October 2017. Mr. Henry currently serves as the President and Chief Executive Officer of Pacific Biosciences, a publicly traded life sciences company, a position he has held since September 2020, and has also served on its board of directors since 2018. Mr. Henry has served on the board of directors of Ginkgo Bioworks, a publicly-traded synthetic biology company, since 2016, and previously served on the board of directors CM Life Sciences III Inc., a publicly-traded special purpose acquisition company, from April 2021 through December 2021. Mr. Henry served as Executive Vice President & Chief Commercial Officer of Illumina, Inc. from 2015 through January 2017, and previously served as Senior Vice President & Chief Commercial Officer from 2014 to 2015, Senior Vice President & General Manager Genomic Solutions from 2012 to 2014, Senior Vice President, Chief Financial Officer & General Manager Life Sciences from 2010 to 2012, Senior Vice President, Corporate Development & Chief Financial Officer from 2009 to 2010, Senior Vice President & Chief Financial Officer from 2007 to 2009, and Vice President & Chief Financial Officer from 2005 to 2006. Prior to joining Illumina, Inc., Mr. Henry served as the Chief Financial Officer of Tickets.com, Inc. from 2003 to 2005. From 1999 to 2003, Mr. Henry served as Vice President, Finance & Corporate Controller of Affymetrix, Inc. (acquired by Thermo Fisher Scientific in 2016). In 1997, Mr. Henry joined Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.), as Corporate Controller, and later as its Chief Accounting Officer from 1997 to 1999. In 1996, Mr. Henry served as General Accounting Manager of Sugen, Inc. Mr. Henry began his career in 1992 at Ernst & Young LLP, where he was a Senior Accountant through 1996. Mr. Henry earned his B.A. in biochemistry and cell biology from the University of California, San Diego, and his M.B.A., with a concentration in finance, from the University of California, Irvine. - Christian Henry自2016年11月起担任董事，自2017年10月起担任董事会主席。Henry先生还担任Ginkgo Bioworks（一家私人合成生物学公司）和Pacific Biosciences（一家上市的生命科学公司）的董事会成员。Henry先生曾于2015年至2017年1月担任Illumina，Inc.执行Vice President兼首席商务官，此前曾于2014年至2015年担任高级副总裁兼首席商务官，2012年至2014年担任高级副总裁基因组解决方案总经理高级副总裁，2010年至2012年，担任生命科学首席财务官和总经理；2009年至2010年，担任企业发展和首席财务官高级副总裁，；2007年至2009年，担任高级副总裁和首席财务官；2005年至2006年，担任Vice President和首席财务官。在加入Illumina，Inc.之前，Henry先生从2003年到2005年担任Tickets.com，Inc.的首席财务官。从1999年到2003年，Henry先生担任赛默飞世尔科技（Thermo Fisher Scientific）于2016年收购的Affymetrix，Inc.的Vice President、财务与公司财务总监。1997年，Henry先生加入Nektar Therapeutics（前身为Inhale Therapeutic Systems，Inc.），担任公司财务总监，后来从1997年到1999年担任其首席会计官。Henry先生于1996年担任Sugen，Inc.的总会计经理。他的职业生涯始于1992年任职Ernst&Young LLP，在那里他曾担任高级会计师（直到1996年）。Henry先生在加州大学圣地亚哥分校（University of California，San Diego）获得生物化学和细胞生物学学士学位，并在加州大学欧文分校（University of California，Irvine）获得金融工商管理硕士学位。
- Christian Henry,has served as a director since November 2016, and as Chairman of Wave Life Sciences Ltd. Board since October 2017. Mr. Henry currently serves as the President and Chief Executive Officer of Pacific Biosciences, a publicly traded life sciences company, a position he has held since September 2020, and has also served on its board of directors since 2018. Mr. Henry has served on the board of directors of Ginkgo Bioworks, a publicly-traded synthetic biology company, since 2016, and previously served on the board of directors CM Life Sciences III Inc., a publicly-traded special purpose acquisition company, from April 2021 through December 2021. Mr. Henry served as Executive Vice President & Chief Commercial Officer of Illumina, Inc. from 2015 through January 2017, and previously served as Senior Vice President & Chief Commercial Officer from 2014 to 2015, Senior Vice President & General Manager Genomic Solutions from 2012 to 2014, Senior Vice President, Chief Financial Officer & General Manager Life Sciences from 2010 to 2012, Senior Vice President, Corporate Development & Chief Financial Officer from 2009 to 2010, Senior Vice President & Chief Financial Officer from 2007 to 2009, and Vice President & Chief Financial Officer from 2005 to 2006. Prior to joining Illumina, Inc., Mr. Henry served as the Chief Financial Officer of Tickets.com, Inc. from 2003 to 2005. From 1999 to 2003, Mr. Henry served as Vice President, Finance & Corporate Controller of Affymetrix, Inc. (acquired by Thermo Fisher Scientific in 2016). In 1997, Mr. Henry joined Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.), as Corporate Controller, and later as its Chief Accounting Officer from 1997 to 1999. In 1996, Mr. Henry served as General Accounting Manager of Sugen, Inc. Mr. Henry began his career in 1992 at Ernst & Young LLP, where he was a Senior Accountant through 1996. Mr. Henry earned his B.A. in biochemistry and cell biology from the University of California, San Diego, and his M.B.A., with a concentration in finance, from the University of California, Irvine.
- Adrian Rawcliffe
-
Adrian Rawcliffe自2017年2月起担任董事。Rawcliffe先生目前担任Adaptimmune治疗有限公司的首席财务官，自2015年以来一直在该公司工作。在加入Adaptimmune之前，罗克里夫曾在GlaxoSmithKline plc担任多个职位，包括2011年至2015年担任高级副总裁金融、北美制药和全球特许经营商；2006年至2011年担任高级副总裁，全球业务开发和研发金融；Vice President，2003年至2005年，负责全球业务发展交易和风险投资；2001年至2003年，负责Vice President的交易结构。从2005年到2006年，Rawcliffe先生担任SR One Ltd.的总裁兼管理合伙人。Rawcliffe先生从1993年到1997年在Coopers&Lybrand（现在的普华永道会计师事务所）担任主管开始他的职业生涯。Rawcliffe先生获得学士学位。获英国达勒姆大学自然科学学士学位。Rawcliffe先生还通过英格兰和威尔士特许会计师协会（ICAEW）接受了特许会计培训。
Adrian Rawcliffe,has served as a director since February 2017. Since September 2019, Mr. Rawcliffe has served as the Chief Executive Officer and on the board of directors of Adaptimmune Therapeutics plc., a publicly traded clinical-stage biopharmaceutical company. Mr. Rawcliffe also serves on the board of directors of Adaptimmune Ltd., a privately-held company and subsidiary of Adaptimmune Therapeutics plc. From 2015 to September 2019, he served as Adaptimmune's Chief Financial Officer. Prior to joining Adaptimmune, Mr. Rawcliffe served in various roles at GlaxoSmithKline plc, including Senior Vice President Finance, North America Pharmaceuticals and Global Franchises from 2011 to 2015; Senior Vice President, Worldwide Business Development and R&D Finance from 2006 to 2011; Vice President, Worldwide Business Development Transactions and Ventures from 2003 to 2005; and Vice President, Deal Structuring from 2001 to 2003. From 2005 to 2006, Mr. Rawcliffe served as the President and Managing Partner of SR One Ltd. Mr. Rawcliffe began his career as a supervisor at Coopers & Lybrand (now PricewaterhouseCoopers) from 1993 to 1997. Mr. Rawcliffe received his B.Sc. in Natural Sciences from the University of Durham, England. Mr. Rawcliffe also received Chartered Accountancy training through The Institute of Chartered Accountants in England and Wales (ICAEW). - Adrian Rawcliffe自2017年2月起担任董事。Rawcliffe先生目前担任Adaptimmune治疗有限公司的首席财务官，自2015年以来一直在该公司工作。在加入Adaptimmune之前，罗克里夫曾在GlaxoSmithKline plc担任多个职位，包括2011年至2015年担任高级副总裁金融、北美制药和全球特许经营商；2006年至2011年担任高级副总裁，全球业务开发和研发金融；Vice President，2003年至2005年，负责全球业务发展交易和风险投资；2001年至2003年，负责Vice President的交易结构。从2005年到2006年，Rawcliffe先生担任SR One Ltd.的总裁兼管理合伙人。Rawcliffe先生从1993年到1997年在Coopers&Lybrand（现在的普华永道会计师事务所）担任主管开始他的职业生涯。Rawcliffe先生获得学士学位。获英国达勒姆大学自然科学学士学位。Rawcliffe先生还通过英格兰和威尔士特许会计师协会（ICAEW）接受了特许会计培训。
- Adrian Rawcliffe,has served as a director since February 2017. Since September 2019, Mr. Rawcliffe has served as the Chief Executive Officer and on the board of directors of Adaptimmune Therapeutics plc., a publicly traded clinical-stage biopharmaceutical company. Mr. Rawcliffe also serves on the board of directors of Adaptimmune Ltd., a privately-held company and subsidiary of Adaptimmune Therapeutics plc. From 2015 to September 2019, he served as Adaptimmune's Chief Financial Officer. Prior to joining Adaptimmune, Mr. Rawcliffe served in various roles at GlaxoSmithKline plc, including Senior Vice President Finance, North America Pharmaceuticals and Global Franchises from 2011 to 2015; Senior Vice President, Worldwide Business Development and R&D Finance from 2006 to 2011; Vice President, Worldwide Business Development Transactions and Ventures from 2003 to 2005; and Vice President, Deal Structuring from 2001 to 2003. From 2005 to 2006, Mr. Rawcliffe served as the President and Managing Partner of SR One Ltd. Mr. Rawcliffe began his career as a supervisor at Coopers & Lybrand (now PricewaterhouseCoopers) from 1993 to 1997. Mr. Rawcliffe received his B.Sc. in Natural Sciences from the University of Durham, England. Mr. Rawcliffe also received Chartered Accountancy training through The Institute of Chartered Accountants in England and Wales (ICAEW).
- Aik Na Tan
-
Aik Na Tan自2020年8月起担任董事。谭女士目前担任新加坡南洋理工大学行政高级副总裁，自2020年1月以来一直担任该职位。从2016年8月加入南大到2017年12月，她担任南大首席财务官。她还于2017年4月至2017年12月担任NTU’；的首席行政官，并于2018年1月至2019年12月担任NTU’；的副总裁（行政）。在加入南大之前，Tan女士于2015年至2016年担任The Chemours CompanySingapore Pte Ltd（从杜邦公司分拆出来的公司）的全球金融转型负责人兼董事总经理。从1994年到2015年，Tan女士在杜邦公司担任过许多全球和区域领导职务，涉及会计，公司财务，六西格玛，金融系统，供应链，运营，财务和战略规划，包括杜邦公司（新加坡）私人有限公司的多个职位，最近从2011年11月到2015年2月担任DuPont Titanium Technologies 首席财务官。谭女士的职业生涯始于Price Waterhouse的税务助理。陈女士拥有新加坡南洋理工大学的会计学士学位，并且是新加坡特许会计师协会的成员。
Aik Na Tan,has served as a director since August 2020. Ms. Tan currently serves as Senior Vice-President (Administration) at Nanyang Technological University, Singapore (NTU), a position she has held since January 2020. From when she joined NTU in August 2016 to December 2017, she served as NTU's Chief Financial Officer. She also served as NTU's Chief Administrative Officer from April 2017 to December 2017 and as NTU's Vice-President (Administration) from January 2018 to December 2019. Prior to joining NTU, Ms. Tan served as Global Finance Transformation Leader & Managing Director of the Chemours Company Singapore Pte Ltd, a spin-off from DuPont, from 2015 to 2016. From 1994 to 2015, Ms. Tan held numerous global and regional leadership roles at DuPont in accounting, corporate treasury, six sigma, financial systems, supply chain, operations, financial and strategic planning, including various positions at DuPont Company (Singapore) Pte Ltd, most recently serving as the Chief Financial Officer of DuPont Titanium Technologies from November 2011 to February 2015. Ms. Tan began her professional career as a tax assistant at Price Waterhouse. Ms. Tan holds a Bachelor of Accountancy degree from the Nanyang Technological University, Singapore, and is a member of the Institute of Singapore Chartered Accountants. - Aik Na Tan自2020年8月起担任董事。谭女士目前担任新加坡南洋理工大学行政高级副总裁，自2020年1月以来一直担任该职位。从2016年8月加入南大到2017年12月，她担任南大首席财务官。她还于2017年4月至2017年12月担任NTU’；的首席行政官，并于2018年1月至2019年12月担任NTU’；的副总裁（行政）。在加入南大之前，Tan女士于2015年至2016年担任The Chemours CompanySingapore Pte Ltd（从杜邦公司分拆出来的公司）的全球金融转型负责人兼董事总经理。从1994年到2015年，Tan女士在杜邦公司担任过许多全球和区域领导职务，涉及会计，公司财务，六西格玛，金融系统，供应链，运营，财务和战略规划，包括杜邦公司（新加坡）私人有限公司的多个职位，最近从2011年11月到2015年2月担任DuPont Titanium Technologies 首席财务官。谭女士的职业生涯始于Price Waterhouse的税务助理。陈女士拥有新加坡南洋理工大学的会计学士学位，并且是新加坡特许会计师协会的成员。
- Aik Na Tan,has served as a director since August 2020. Ms. Tan currently serves as Senior Vice-President (Administration) at Nanyang Technological University, Singapore (NTU), a position she has held since January 2020. From when she joined NTU in August 2016 to December 2017, she served as NTU's Chief Financial Officer. She also served as NTU's Chief Administrative Officer from April 2017 to December 2017 and as NTU's Vice-President (Administration) from January 2018 to December 2019. Prior to joining NTU, Ms. Tan served as Global Finance Transformation Leader & Managing Director of the Chemours Company Singapore Pte Ltd, a spin-off from DuPont, from 2015 to 2016. From 1994 to 2015, Ms. Tan held numerous global and regional leadership roles at DuPont in accounting, corporate treasury, six sigma, financial systems, supply chain, operations, financial and strategic planning, including various positions at DuPont Company (Singapore) Pte Ltd, most recently serving as the Chief Financial Officer of DuPont Titanium Technologies from November 2011 to February 2015. Ms. Tan began her professional career as a tax assistant at Price Waterhouse. Ms. Tan holds a Bachelor of Accountancy degree from the Nanyang Technological University, Singapore, and is a member of the Institute of Singapore Chartered Accountants.
- Mark H. N. Corrigan
-
Mark H. N. Corrigan， 硕士学位。a Class II类董事，自2009年12月起担任 Zalicus董事。自2010年1月起担任 Zalicus总裁和首席执行官。2003年4月到2009年12月担任Sepracor Inc.（一家公开上市制造公司）研发部执行副总裁。加入Sepracor Inc.之前，他在Pharmacia & Upjohn（一家公开上市制造公司，2002年被Pfizer, Inc.收购）工作10年，最近的职位是担任 Global Clinical Research and Experimental Medicine集团副总裁。加入制药行业之前，他在the University of North Carolina Medical School进行5年的学术研究，主要研究心理神经内分泌学。他还担任 Cubist Pharmaceuticals, Inc.（一家公开上市生物制药公司）董事。他持有佛吉尼亚大学（the University of Virginia）文学学士学位以及硕士学位，之后不久还在 Cornell and Maine Medical Center受到了精神病学的特殊训练。
Mark H. N. Corrigan,has served as a director since September 2019. Since June 2021, Dr. Corrigan has served as a member of the board of directors of Nabriva Therapeutics plc, a publicly traded commercial-stage biopharmaceutical company, and previously served on its board of directors from June 2017 to May 2020. Dr. Corrigan also currently serves as chairman of the board of directors of Elios Therapeutics, LLC, a privately-held development-stage immuno-oncology company. Dr. Corrigan served as the Chief Executive Officer of Correvio Pharma Corp. from March 2019 to May 2020. Prior to joining Correvio, Dr. Corrigan was President of Research and Development at Tremeau Pharmaceuticals (of which he is also a co-founder) from 2016 to March 2019, and continues to serve on its board of directors. Dr. Corrigan served as President and Chief Executive Officer of Zalicus, Inc. (formerly CombinatoRx) from 2010 to 2014. Prior to that time, from 2003 to 2009, Dr. Corrigan held the role of Executive Vice President, Research and Development at Sepracor Inc. From 2000 to 2003, Dr. Corrigan served as Group Vice President, Clinical Research & Experimental Medicine at Pharmacia Corporation. Prior to this, Dr. Corrigan held various roles at The Upjohn Company, The University of North Carolina, and the National Institute of Mental Health Center for Psychoneuroendocrinology in Adults and Children at Dorthea Dix Hospital. Dr. Corrigan previously served as a member of the board of directors of Avanir Pharmaceuticals, Inc., CoLucid Pharmaceuticals, Inc., Correvio Pharma Corp., and Cubist Pharmaceuticals, Inc. Dr. Corrigan holds an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University. He received a Bachelor of Arts in Psychology from the University of Virginia. - Mark H. N. Corrigan， 硕士学位。a Class II类董事，自2009年12月起担任 Zalicus董事。自2010年1月起担任 Zalicus总裁和首席执行官。2003年4月到2009年12月担任Sepracor Inc.（一家公开上市制造公司）研发部执行副总裁。加入Sepracor Inc.之前，他在Pharmacia & Upjohn（一家公开上市制造公司，2002年被Pfizer, Inc.收购）工作10年，最近的职位是担任 Global Clinical Research and Experimental Medicine集团副总裁。加入制药行业之前，他在the University of North Carolina Medical School进行5年的学术研究，主要研究心理神经内分泌学。他还担任 Cubist Pharmaceuticals, Inc.（一家公开上市生物制药公司）董事。他持有佛吉尼亚大学（the University of Virginia）文学学士学位以及硕士学位，之后不久还在 Cornell and Maine Medical Center受到了精神病学的特殊训练。
- Mark H. N. Corrigan,has served as a director since September 2019. Since June 2021, Dr. Corrigan has served as a member of the board of directors of Nabriva Therapeutics plc, a publicly traded commercial-stage biopharmaceutical company, and previously served on its board of directors from June 2017 to May 2020. Dr. Corrigan also currently serves as chairman of the board of directors of Elios Therapeutics, LLC, a privately-held development-stage immuno-oncology company. Dr. Corrigan served as the Chief Executive Officer of Correvio Pharma Corp. from March 2019 to May 2020. Prior to joining Correvio, Dr. Corrigan was President of Research and Development at Tremeau Pharmaceuticals (of which he is also a co-founder) from 2016 to March 2019, and continues to serve on its board of directors. Dr. Corrigan served as President and Chief Executive Officer of Zalicus, Inc. (formerly CombinatoRx) from 2010 to 2014. Prior to that time, from 2003 to 2009, Dr. Corrigan held the role of Executive Vice President, Research and Development at Sepracor Inc. From 2000 to 2003, Dr. Corrigan served as Group Vice President, Clinical Research & Experimental Medicine at Pharmacia Corporation. Prior to this, Dr. Corrigan held various roles at The Upjohn Company, The University of North Carolina, and the National Institute of Mental Health Center for Psychoneuroendocrinology in Adults and Children at Dorthea Dix Hospital. Dr. Corrigan previously served as a member of the board of directors of Avanir Pharmaceuticals, Inc., CoLucid Pharmaceuticals, Inc., Correvio Pharma Corp., and Cubist Pharmaceuticals, Inc. Dr. Corrigan holds an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University. He received a Bachelor of Arts in Psychology from the University of Virginia.
- Gregory L. Verdine
-
Gregory L. Verdine，他是Wave Life Sciences Ltd.的创始人之一，自2013年7月起担任Wave Life Sciences Ltd. 董事。从Wave Life Sciences Ltd.成立到2013年12月担任总裁、首席执行官和首席科学官，并担任Wave Life Sciences Ltd.董事长。2013年7月至2017年9月担任董事会成员。1989年以来，他曾担任哈佛大学和哈佛医学院干细胞和再生生物系、化学和化学生物系的欧文化学教授；他现在是欧文化学荣誉教授。Verdine博士于2013年共同创立了非营利性的Gloucester Marine Genomics Institute和Gloucester Biotechnology Academy，并担任创始总裁直到2016年。他是Fog Pharmaceuticals Inc.（一家私营公司）的联合创始人，目前担任该公司的董事会副主席。他也是私人控股公司LifeMine Therapeutics Inc.的总裁兼首席执行官和董事会成员。他也是Warp Drive Bio（与Revolution Medicines, Inc.（纳斯达克股票代码：RVMD）合并）的创始人，并从公司2012年成立到2016年4月担任各种职务，从首席科学官到首席执行官。Verdine博士创立了Enanta制药公司，并从1990年到2013年首次公开募股担任其董事会成员。他曾担任WuXi Healthcare Ventures、AppleTree Ventures、TPG Biotech和Third Rock Ventures的风险合伙人。他曾任职于美国国家癌症研究所的科学顾问委员会，Memorial Sloan Kettering癌症中心的科学顾问委员会，并曾担任Shin Nippon Biomedical Laboratories Ltd, Hofmann La Roche, Pfizer和Merck的高级顾问。他也是Eleven Biotherapeutics、Tokai Therapeutics、Aileron Therapeutics和Gloucester Pharmaceuticals（2010年被Celgene收购）的联合创始人。他还曾担任the Dana-Farber Cancer Institute的化学生物学倡议和癌症化学生物学项目的董事。他在哥伦比亚大学获得化学博士学位，并在麻省理工学院和哈佛医学院完成了分子生物学的博士后工作。
Gregory L. Verdine,is one of Wave Life Sciences Ltd. founders and has served as a director since July 2013. He was Wave Life Sciences Ltd. President, Chief Executive Officer and Chief Scientific Officer from Wave Life Sciences Ltd. inception through December 2013 and served as Chairman of Wave Life Sciences Ltd. Board from July 2013 through September 2017. Since 1989, Dr. Verdine has served as the Erving Professor of Chemistry in the Department of Stem Cell and Regenerative Biology and the Department of Chemistry and Chemical Biology at Harvard University and Harvard Medical School; he is now Erving Professor of Chemistry, Emeritus. Dr. Verdine co-founded the non-profit Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy in 2013 and served as the Founding President until 2016. He is the co-founder of Fog Pharmaceuticals Inc., a privately-held company, and currently serves as Vice Chairman of the board of directors for the company. He is also President and Chief Executive Officer and serves on the board of directors of LifeMine Therapeutics Inc., a privately-held company. He is also the founder of Warp Drive Bio (merged with Revolution Medicines, Inc. (Nasdaq: RVMD)) and served in various roles, from Chief Scientific Officer to Chief Executive Officer, from the company's inception in 2012 until April 2016. Dr. Verdine founded Enanta Pharmaceuticals and served as a member of its board of directors from 1990 through its initial public offering in 2013. He has served as a Venture Partner at WuXi Healthcare Ventures, AppleTree Ventures, TPG Biotech and Third Rock Ventures. He has served on the Board of Scientific Counselors of the National Cancer Institute, and on the Board of Scientific Consultants of the Memorial Sloan Kettering Cancer Center, and was a Senior Advisor to Shin Nippon Biomedical Laboratories Ltd, Hofmann La Roche, Pfizer and Merck. Dr. Verdine is also a co-founder of Eleven Biotherapeutics, Tokai Therapeutics, Aileron Therapeutics, and Gloucester Pharmaceuticals (acquired by Celgene in 2010). He has also served as a director of the Chemical Biology Initiative and the Program in Cancer Chemical Biology at the Dana-Farber Cancer Institute. Dr. Verdine received his Ph.D. in Chemistry from Columbia University and completed postdoctoral work in Molecular Biology at the Massachusetts Institute of Technology and Harvard Medical School. - Gregory L. Verdine，他是Wave Life Sciences Ltd.的创始人之一，自2013年7月起担任Wave Life Sciences Ltd. 董事。从Wave Life Sciences Ltd.成立到2013年12月担任总裁、首席执行官和首席科学官，并担任Wave Life Sciences Ltd.董事长。2013年7月至2017年9月担任董事会成员。1989年以来，他曾担任哈佛大学和哈佛医学院干细胞和再生生物系、化学和化学生物系的欧文化学教授；他现在是欧文化学荣誉教授。Verdine博士于2013年共同创立了非营利性的Gloucester Marine Genomics Institute和Gloucester Biotechnology Academy，并担任创始总裁直到2016年。他是Fog Pharmaceuticals Inc.（一家私营公司）的联合创始人，目前担任该公司的董事会副主席。他也是私人控股公司LifeMine Therapeutics Inc.的总裁兼首席执行官和董事会成员。他也是Warp Drive Bio（与Revolution Medicines, Inc.（纳斯达克股票代码：RVMD）合并）的创始人，并从公司2012年成立到2016年4月担任各种职务，从首席科学官到首席执行官。Verdine博士创立了Enanta制药公司，并从1990年到2013年首次公开募股担任其董事会成员。他曾担任WuXi Healthcare Ventures、AppleTree Ventures、TPG Biotech和Third Rock Ventures的风险合伙人。他曾任职于美国国家癌症研究所的科学顾问委员会，Memorial Sloan Kettering癌症中心的科学顾问委员会，并曾担任Shin Nippon Biomedical Laboratories Ltd, Hofmann La Roche, Pfizer和Merck的高级顾问。他也是Eleven Biotherapeutics、Tokai Therapeutics、Aileron Therapeutics和Gloucester Pharmaceuticals（2010年被Celgene收购）的联合创始人。他还曾担任the Dana-Farber Cancer Institute的化学生物学倡议和癌症化学生物学项目的董事。他在哥伦比亚大学获得化学博士学位，并在麻省理工学院和哈佛医学院完成了分子生物学的博士后工作。
- Gregory L. Verdine,is one of Wave Life Sciences Ltd. founders and has served as a director since July 2013. He was Wave Life Sciences Ltd. President, Chief Executive Officer and Chief Scientific Officer from Wave Life Sciences Ltd. inception through December 2013 and served as Chairman of Wave Life Sciences Ltd. Board from July 2013 through September 2017. Since 1989, Dr. Verdine has served as the Erving Professor of Chemistry in the Department of Stem Cell and Regenerative Biology and the Department of Chemistry and Chemical Biology at Harvard University and Harvard Medical School; he is now Erving Professor of Chemistry, Emeritus. Dr. Verdine co-founded the non-profit Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy in 2013 and served as the Founding President until 2016. He is the co-founder of Fog Pharmaceuticals Inc., a privately-held company, and currently serves as Vice Chairman of the board of directors for the company. He is also President and Chief Executive Officer and serves on the board of directors of LifeMine Therapeutics Inc., a privately-held company. He is also the founder of Warp Drive Bio (merged with Revolution Medicines, Inc. (Nasdaq: RVMD)) and served in various roles, from Chief Scientific Officer to Chief Executive Officer, from the company's inception in 2012 until April 2016. Dr. Verdine founded Enanta Pharmaceuticals and served as a member of its board of directors from 1990 through its initial public offering in 2013. He has served as a Venture Partner at WuXi Healthcare Ventures, AppleTree Ventures, TPG Biotech and Third Rock Ventures. He has served on the Board of Scientific Counselors of the National Cancer Institute, and on the Board of Scientific Consultants of the Memorial Sloan Kettering Cancer Center, and was a Senior Advisor to Shin Nippon Biomedical Laboratories Ltd, Hofmann La Roche, Pfizer and Merck. Dr. Verdine is also a co-founder of Eleven Biotherapeutics, Tokai Therapeutics, Aileron Therapeutics, and Gloucester Pharmaceuticals (acquired by Celgene in 2010). He has also served as a director of the Chemical Biology Initiative and the Program in Cancer Chemical Biology at the Dana-Farber Cancer Institute. Dr. Verdine received his Ph.D. in Chemistry from Columbia University and completed postdoctoral work in Molecular Biology at the Massachusetts Institute of Technology and Harvard Medical School.
- Peter Kolchinsky
-
Peter Kolchinsky，他是一名博士，自2021年3月起担任Icosavax, Inc.的董事。他自2013年7月在Therapeutics Acquisition Corp.担任董事。自2004年9月，他在RA Capital公司担任创始合伙人和证券投资经理。他在个人和公共投资领域都十分活跃，投资领域涉及制药、医疗设备、诊断和生命科学工具行业。他编写了一本名为《生物技术入门的经营者指南》的电子书籍，并在American Fertility Association公司担任董事。目前，他在CellScape 公司、Zipline Medical公司、Lantos Technologies公司、Periphagen公司、Calimmune公司和 PiloFocus这六家公司担任董事。他曾在国家科学院（National Academies of Sciences）的全球科技委员会任职。他在哈佛大学（Harvard University）获得病毒学博士学位，并在美国康乃尔大学（Cornell University）获得学士学位。
Peter Kolchinsky,has served on Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. Dr. Kolchinsky previously served on the board of directors of Private ARS Pharma from August 2021 to November 2022. Dr. Kolchinsky has more than 20 years of experience in healthcare investing and is the Founder of and a Managing Partner at RA Capital Management, L.P. RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, diagnostics and research tools. Dr. Kolchinsky has also served on the boards of directors of ICOSAVAX, Inc. (Nasdaq: ICVX), a vaccine development company, since March 2021, and WAVE Life Sciences, Ltd. (Nasdaq: WVE), a biotechnology company focused on delivering therapies for patients with serious, genetically-defined diseases, since January 2015, in addition to a number of private companies. Dr. Kolchinsky was previously a member of the board of directors of Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), from July 2013 to December 2019, Forma Therapeutics Holdings, Inc. (formerly Nasdaq: FMTX), from December 2019 to October 2022 and Synthorx, Inc. (formerly Nasdaq: THOR), from May 2018 to January 2020, all public pharmaceutical companies. Dr. Kolchinsky also served on the Board of Global Science and Technology for the National Academy of Sciences, and is the author of "The Great American Drug Deal" and "The Entrepreneur's Guide to a Biotech Startup". He founded the non-profit No Patient Left Behind to advocate for healthcare reforms that would solve affordability and promote continued biomedical innovation. Dr. Kolchinsky holds a BA from Cornell University and a Ph.D. in Virology from Harvard University. - Peter Kolchinsky，他是一名博士，自2021年3月起担任Icosavax, Inc.的董事。他自2013年7月在Therapeutics Acquisition Corp.担任董事。自2004年9月，他在RA Capital公司担任创始合伙人和证券投资经理。他在个人和公共投资领域都十分活跃，投资领域涉及制药、医疗设备、诊断和生命科学工具行业。他编写了一本名为《生物技术入门的经营者指南》的电子书籍，并在American Fertility Association公司担任董事。目前，他在CellScape 公司、Zipline Medical公司、Lantos Technologies公司、Periphagen公司、Calimmune公司和 PiloFocus这六家公司担任董事。他曾在国家科学院（National Academies of Sciences）的全球科技委员会任职。他在哈佛大学（Harvard University）获得病毒学博士学位，并在美国康乃尔大学（Cornell University）获得学士学位。
- Peter Kolchinsky,has served on Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. Dr. Kolchinsky previously served on the board of directors of Private ARS Pharma from August 2021 to November 2022. Dr. Kolchinsky has more than 20 years of experience in healthcare investing and is the Founder of and a Managing Partner at RA Capital Management, L.P. RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, diagnostics and research tools. Dr. Kolchinsky has also served on the boards of directors of ICOSAVAX, Inc. (Nasdaq: ICVX), a vaccine development company, since March 2021, and WAVE Life Sciences, Ltd. (Nasdaq: WVE), a biotechnology company focused on delivering therapies for patients with serious, genetically-defined diseases, since January 2015, in addition to a number of private companies. Dr. Kolchinsky was previously a member of the board of directors of Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), from July 2013 to December 2019, Forma Therapeutics Holdings, Inc. (formerly Nasdaq: FMTX), from December 2019 to October 2022 and Synthorx, Inc. (formerly Nasdaq: THOR), from May 2018 to January 2020, all public pharmaceutical companies. Dr. Kolchinsky also served on the Board of Global Science and Technology for the National Academy of Sciences, and is the author of "The Great American Drug Deal" and "The Entrepreneur's Guide to a Biotech Startup". He founded the non-profit No Patient Left Behind to advocate for healthcare reforms that would solve affordability and promote continued biomedical innovation. Dr. Kolchinsky holds a BA from Cornell University and a Ph.D. in Virology from Harvard University.
高管简历
中英对照 | 中文 | 英文- Paul B. Bolno
Paul B. Bolno，自2013年12月起担任公司的总裁和首席执行官，也是董事。在加入公司之前，他在GlaxoSmithKline担任不同的职位（2009-2013年），包括全球业务拓展副总裁，亚洲（Asia）业务拓展和投资负责人；全球神经科学业务拓展负责人；新加坡（Singapore）Glaxo Welcome Manufacturing, Pte. Ltd.的董事；肿瘤科业务拓展副总裁，他建立了GlaxoSmithKline的全球肿瘤业务并担任肿瘤执行团队、肿瘤商业董事会和癌症研究执行团队的成员。在GlaxoSmithKline之前，他担任Two River 有限责任公司（Two River LLC，一家健康保健私人股权公司）的研究董事（2004-2009年）。他拥有MCP哈内曼医学院（MCP-Hahnemann School of Medicine）医学学位和德雷克塞尔大学（Drexel University）工商管理硕士学位。他是德雷克塞尔大学医学院（Drexel University College of Medicine）的普通外科住院医师和心胸外科博士后研究师。
Paul B. Bolno,has served as Wave Life Sciences Ltd. President and Chief Executive Officer since December 2013 and as a director since April 2014. Since June 2020, Dr. Bolno has also served on the board of directors of SQZ Biotechnologies, a publicly-traded life sciences company, and since May 2020, he has served as Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator (NATA) in the United Kingdom. Prior to joining Wave Life Sciences Ltd. , he served at GlaxoSmithKline from 2009 to 2013 in various roles, including Vice President, Worldwide Business Development—Head of Asia BD and Investments, Head of Global Neuroscience BD, a director of Glaxo Welcome Manufacturing, Pte. Ltd. in Singapore and Vice President, Business Development for the Oncology Business Unit, where he helped establish GlaxoSmithKline's global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GlaxoSmithKline, he served as director of Research at Two River LLC, a health care private equity firm from 2004 to 2009. Dr. Bolno earned a medical degree from MCP-Hahnemann School of Medicine and an M.B.A. from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine.- Paul B. Bolno，自2013年12月起担任公司的总裁和首席执行官，也是董事。在加入公司之前，他在GlaxoSmithKline担任不同的职位（2009-2013年），包括全球业务拓展副总裁，亚洲（Asia）业务拓展和投资负责人；全球神经科学业务拓展负责人；新加坡（Singapore）Glaxo Welcome Manufacturing, Pte. Ltd.的董事；肿瘤科业务拓展副总裁，他建立了GlaxoSmithKline的全球肿瘤业务并担任肿瘤执行团队、肿瘤商业董事会和癌症研究执行团队的成员。在GlaxoSmithKline之前，他担任Two River 有限责任公司（Two River LLC，一家健康保健私人股权公司）的研究董事（2004-2009年）。他拥有MCP哈内曼医学院（MCP-Hahnemann School of Medicine）医学学位和德雷克塞尔大学（Drexel University）工商管理硕士学位。他是德雷克塞尔大学医学院（Drexel University College of Medicine）的普通外科住院医师和心胸外科博士后研究师。
- Paul B. Bolno,has served as Wave Life Sciences Ltd. President and Chief Executive Officer since December 2013 and as a director since April 2014. Since June 2020, Dr. Bolno has also served on the board of directors of SQZ Biotechnologies, a publicly-traded life sciences company, and since May 2020, he has served as Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator (NATA) in the United Kingdom. Prior to joining Wave Life Sciences Ltd. , he served at GlaxoSmithKline from 2009 to 2013 in various roles, including Vice President, Worldwide Business Development—Head of Asia BD and Investments, Head of Global Neuroscience BD, a director of Glaxo Welcome Manufacturing, Pte. Ltd. in Singapore and Vice President, Business Development for the Oncology Business Unit, where he helped establish GlaxoSmithKline's global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GlaxoSmithKline, he served as director of Research at Two River LLC, a health care private equity firm from 2004 to 2009. Dr. Bolno earned a medical degree from MCP-Hahnemann School of Medicine and an M.B.A. from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine.
- Christopher Francis
Christopher Francis，自2014年4月起担任公司的副总裁和业务拓展负责人。在加入公司之前，他在GlaxoSmithKline Oncology担任高级运恒、战略和拓展职位（2009-2014年），也是建立GlaxoSmithKline的罕见疾病单位的团队成员。在GlaxoSmithKline之前，Francis博士是Two River有限责任公司（Two River LLC）的健康保健私人股权助理（2008-2009年）。他在IMS Health开始他在药物定价和偿还咨询的职业生涯。Francis博士获得了墨尔本大学（University of Melbourne）生物化学和细胞生物的本科和研究生学位，也是剑桥大学（University of Cambridge）博士研究助理。
Christopher Francis,has served as Wave Life Sciences Ltd. Senior Vice President, Corporate Development, Head of Emerging Areas since May 2017. During the period January 2017 to May 2017, Dr. Francis served as Wave Life Sciences Ltd. Senior Vice President, Corporate Development & Portfolio Management. Prior to that, Dr. Francis served as Wave Life Sciences Ltd. Vice President, Head of Business Development since April 2014. Prior to joining Wave Life Sciences Ltd. , Dr. Francis held senior operational, strategic and business development roles within GlaxoSmithKline Oncology from 2009 to 2014 and was a member of the team that established GlaxoSmithKline's Rare Disease Unit. Before GlaxoSmithKline, Dr. Francis was a health care private equity associate at Two River LLC from 2008 to 2009. He began his career in pharmaceutical pricing and reimbursement consulting at IMS Health. Dr. Francis earned undergraduate and graduate degrees in Biochemistry and Molecular Biology from the University of Melbourne and was a doctoral research associate at the University of Cambridge.- Christopher Francis，自2014年4月起担任公司的副总裁和业务拓展负责人。在加入公司之前，他在GlaxoSmithKline Oncology担任高级运恒、战略和拓展职位（2009-2014年），也是建立GlaxoSmithKline的罕见疾病单位的团队成员。在GlaxoSmithKline之前，Francis博士是Two River有限责任公司（Two River LLC）的健康保健私人股权助理（2008-2009年）。他在IMS Health开始他在药物定价和偿还咨询的职业生涯。Francis博士获得了墨尔本大学（University of Melbourne）生物化学和细胞生物的本科和研究生学位，也是剑桥大学（University of Cambridge）博士研究助理。
- Christopher Francis,has served as Wave Life Sciences Ltd. Senior Vice President, Corporate Development, Head of Emerging Areas since May 2017. During the period January 2017 to May 2017, Dr. Francis served as Wave Life Sciences Ltd. Senior Vice President, Corporate Development & Portfolio Management. Prior to that, Dr. Francis served as Wave Life Sciences Ltd. Vice President, Head of Business Development since April 2014. Prior to joining Wave Life Sciences Ltd. , Dr. Francis held senior operational, strategic and business development roles within GlaxoSmithKline Oncology from 2009 to 2014 and was a member of the team that established GlaxoSmithKline's Rare Disease Unit. Before GlaxoSmithKline, Dr. Francis was a health care private equity associate at Two River LLC from 2008 to 2009. He began his career in pharmaceutical pricing and reimbursement consulting at IMS Health. Dr. Francis earned undergraduate and graduate degrees in Biochemistry and Molecular Biology from the University of Melbourne and was a doctoral research associate at the University of Cambridge.
- Kyle Moran
Kyle Moran，自2014年7月起担任公司的副总裁和财务负责人。在加入公司之前，Moran先生担任Veroha股份有限公司（Veroha, Inc.，一家信息保险软件公司，专注于电子公证解决方案）的财务总监和运营总监（2010-2014年）。他也是Context Financial Services有限责任公司（Context Financial Services, LLC，精品咨询公司，给处于快速扩张的初创公司和中型公司提供临时财务总监服务或者需要专业的财务法律顾问）创世合伙人，2006-2014年在那边工作。另外，Moran先生在领先的全球财务服务公司担任高级运营和财务职位，包括Zurich Scudder Investments、JPMorgan Chase和 Putnam Investments。Moran先生拥有波士顿大学（Boston College）经济学学士学位，并参加布兰迪斯大学（Brandeis University）国际经济学和财务的伦贝格（Lemberg）硕士项目。Moran先生是一名注册财务分析师。
Kyle Moran,has served as Wave Life Sciences Ltd. Chief Financial Officer since December 2020. Prior to this appointment, Mr. Moran served as Wave Life Sciences Ltd. Vice President, Head of Finance from July 2014 to August 2016; Vice President, Technical Operations from August 2016 to December 2017; Senior Vice President, Technical Operations, from December 2017 to November 2018; Senior Vice President, Operations and Business Analytics from November 2018 to January 2020; and most recently as Senior Vice President, Finance and Operations from January 2020 through his promotion to Chief Financial Officer in December 2020. Prior to joining Wave Life Sciences Ltd. , Mr. Moran served as Chief Financial Officer and Chief Operating Officer of Veroha, Inc., an information assurance software company focused on electronic notary solutions, from 2010 to 2014. He was also a founding partner of Context Financial Services, LLC, a boutique consulting firm that provided interim CFO-services to start-up and middle market companies undergoing rapid expansion or needing expert financial counsel and worked there from 2006 to 2014. In addition, Mr. Moran held senior operational and financial roles at leading global financial services firms, including Zurich Scudder Investments, JPMorgan Chase and Putnam Investments. Mr. Moran holds a bachelor's degree in Economics from Boston College and attended the Lemberg Master's Program in International Economics and Finance at Brandeis University. Mr. Moran is a Chartered Financial Analyst.- Kyle Moran，自2014年7月起担任公司的副总裁和财务负责人。在加入公司之前，Moran先生担任Veroha股份有限公司（Veroha, Inc.，一家信息保险软件公司，专注于电子公证解决方案）的财务总监和运营总监（2010-2014年）。他也是Context Financial Services有限责任公司（Context Financial Services, LLC，精品咨询公司，给处于快速扩张的初创公司和中型公司提供临时财务总监服务或者需要专业的财务法律顾问）创世合伙人，2006-2014年在那边工作。另外，Moran先生在领先的全球财务服务公司担任高级运营和财务职位，包括Zurich Scudder Investments、JPMorgan Chase和 Putnam Investments。Moran先生拥有波士顿大学（Boston College）经济学学士学位，并参加布兰迪斯大学（Brandeis University）国际经济学和财务的伦贝格（Lemberg）硕士项目。Moran先生是一名注册财务分析师。
- Kyle Moran,has served as Wave Life Sciences Ltd. Chief Financial Officer since December 2020. Prior to this appointment, Mr. Moran served as Wave Life Sciences Ltd. Vice President, Head of Finance from July 2014 to August 2016; Vice President, Technical Operations from August 2016 to December 2017; Senior Vice President, Technical Operations, from December 2017 to November 2018; Senior Vice President, Operations and Business Analytics from November 2018 to January 2020; and most recently as Senior Vice President, Finance and Operations from January 2020 through his promotion to Chief Financial Officer in December 2020. Prior to joining Wave Life Sciences Ltd. , Mr. Moran served as Chief Financial Officer and Chief Operating Officer of Veroha, Inc., an information assurance software company focused on electronic notary solutions, from 2010 to 2014. He was also a founding partner of Context Financial Services, LLC, a boutique consulting firm that provided interim CFO-services to start-up and middle market companies undergoing rapid expansion or needing expert financial counsel and worked there from 2006 to 2014. In addition, Mr. Moran held senior operational and financial roles at leading global financial services firms, including Zurich Scudder Investments, JPMorgan Chase and Putnam Investments. Mr. Moran holds a bachelor's degree in Economics from Boston College and attended the Lemberg Master's Program in International Economics and Finance at Brandeis University. Mr. Moran is a Chartered Financial Analyst.
- Chandra Vargeese
Chandra Vargeese，曾担任Wave Life Sciences Ltd.首席技术官，平台发现科学主管（2020年5月以来）。2014年8月至2020年4月期间，Vargeese博士担任高级副总裁，负责药物发现。加入Wave Life Sciences Ltd.之前，她曾担任Novartis的执行董事兼RNA化学和递送主管（2008年至2014年）。加入Novartis之前，她在Merck & Co.的RNA治疗部门领导siRNA递送，在那里她担任RNA化学和递送的高级董事兼主管。她通过收购Sirna Therapeutics加入Merck & Co.，担任化学副总裁。在Sirna之前，她曾担任NeXstar Pharmaceuticals的化学副总监，也是Macugen （pegaptanib）的共同发明者，Macugen （pegaptanib）是一种被批准用于治疗湿性AMD的疗法。Vargeese博士在印度班加罗尔的印度科学研究所获得有机化学博士学位，并在University of Rhode Island完成博士后工作。
Chandra Vargeese,has served as Wave Life Sciences Ltd. Chief Technology Officer, Head of Platform Discovery Sciences since May 2020. During the period of August 2014 to April 2020, Dr. Vargeese served as Senior Vice President, Head of Drug Discovery. Before joining Wave Life Sciences Ltd. , Dr. Vargeese served as Novartis' Executive Director and Head of RNA Chemistry and Delivery, a position she held from 2008 to 2014. Prior to joining Novartis, Dr. Vargeese led siRNA delivery in the RNA Therapeutics division at Merck & Co., where she served as Senior Director and Head of RNA Chemistry and Delivery. Dr. Vargeese joined Merck through its acquisition of Sirna Therapeutics, where she was Vice President of Chemistry. Before Sirna, Dr. Vargeese served as Associate Director of Chemistry at NeXstar Pharmaceuticals and is the co-inventor of Macugen (pegaptanib), an approved therapy for treating wet AMD. Dr. Vargeese earned a Ph.D. in Organic Chemistry at the Indian Institute of Science, Bangalore, India and completed post-doctoral work at the University of Rhode Island.- Chandra Vargeese，曾担任Wave Life Sciences Ltd.首席技术官，平台发现科学主管（2020年5月以来）。2014年8月至2020年4月期间，Vargeese博士担任高级副总裁，负责药物发现。加入Wave Life Sciences Ltd.之前，她曾担任Novartis的执行董事兼RNA化学和递送主管（2008年至2014年）。加入Novartis之前，她在Merck & Co.的RNA治疗部门领导siRNA递送，在那里她担任RNA化学和递送的高级董事兼主管。她通过收购Sirna Therapeutics加入Merck & Co.，担任化学副总裁。在Sirna之前，她曾担任NeXstar Pharmaceuticals的化学副总监，也是Macugen （pegaptanib）的共同发明者，Macugen （pegaptanib）是一种被批准用于治疗湿性AMD的疗法。Vargeese博士在印度班加罗尔的印度科学研究所获得有机化学博士学位，并在University of Rhode Island完成博士后工作。
- Chandra Vargeese,has served as Wave Life Sciences Ltd. Chief Technology Officer, Head of Platform Discovery Sciences since May 2020. During the period of August 2014 to April 2020, Dr. Vargeese served as Senior Vice President, Head of Drug Discovery. Before joining Wave Life Sciences Ltd. , Dr. Vargeese served as Novartis' Executive Director and Head of RNA Chemistry and Delivery, a position she held from 2008 to 2014. Prior to joining Novartis, Dr. Vargeese led siRNA delivery in the RNA Therapeutics division at Merck & Co., where she served as Senior Director and Head of RNA Chemistry and Delivery. Dr. Vargeese joined Merck through its acquisition of Sirna Therapeutics, where she was Vice President of Chemistry. Before Sirna, Dr. Vargeese served as Associate Director of Chemistry at NeXstar Pharmaceuticals and is the co-inventor of Macugen (pegaptanib), an approved therapy for treating wet AMD. Dr. Vargeese earned a Ph.D. in Organic Chemistry at the Indian Institute of Science, Bangalore, India and completed post-doctoral work at the University of Rhode Island.